Schroder Investment Management Group’s KalVista Pharmaceuticals KALV Stock Holding History

Schroder Investment Management Group’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.3M	Sell	506,743 -665,012	-57%	-$10.7M	0.01%	686
2025 Q4	$18.9M	Buy	1,171,755 +13,298	+1%	+$176K	0.01%	524
2025 Q3	$14.1M	Buy	1,158,457 +603,499	+109%	+$8.34M	0.01%	598
2025 Q2	$6.27M	Sell	554,958 -313,053	-36%	-$3.83M	0.01%	730
2025 Q1	$10.4M	Buy	868,011 +62,566	+8%	+$639K	0.01%	634
2024 Q4	$6.76M	Buy	805,445 +374,213	+87%	+$3.88M	0.01%	719
2024 Q3	$5.32M	Sell	431,232 -36,766	-8%	-$462K	0.01%	775
2024 Q2	$5.51M	Buy	467,998 +213,224	+84%	+$2.49M	0.01%	761
2024 Q1	$3.02M	Buy	+254,774	New	+$3.4M	﹤0.01%	866

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Schroder Investment Management Group's KALV Position: Q1 2026 in Review

Schroder Investment Management Group reduced its KalVista Pharmaceuticals (KALV) stake by 57% in Q1 2026, selling an estimated $10.7M and leaving 506,743 shares worth $9.3M. The position accounts for 0.01% of the portfolio, ranked #686.

Schroder Investment Management Group first reported a position in KALV in Q1 2024 and has held it in 9 quarters since. The position peaked at $18.9M in Q4 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Schroder Investment Management Group held 506,743 shares of KalVista Pharmaceuticals worth $9.3M as of Q1 2026.
Schroder Investment Management Group sold 665,012 KalVista Pharmaceuticals shares in Q1 2026, an estimated $10.7M.
KalVista Pharmaceuticals made up 0.01% of Schroder Investment Management Group's portfolio in Q1 2026, its #686 holding.
Schroder Investment Management Group first reported a position in KalVista Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Schroder Investment Management Group's KalVista Pharmaceuticals position peaked at $18.9M in Q4 2025.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Schroder Investment Management Group's 13F filing for Q1 2026, filed 14 May 2026.